Marijke Vroomen Durning, RN | Authors

Articles

NCI-MATCH Trial Explores Tumor-Agnostic Approach

February 03, 2021

A tumor-agnostic approach in which treatment is developed based on a tumor’s genetic and molecular features without regard to the cancer type or primary tumor location in the body, is the focus of the National Cancer Institute -MATCH trial.

Protocol Management, Off-the-Shelf Therapies Help Bring CAR T Into More Settings

May 12, 2020

Relevant professional meetings and oncology publications exploded with research and news about chimeric antigen receptor T cells, and this cellular therapy strategy is now being explored across hematologic and solid malignancies.

Growth Factors Play Emerging Role in Bladder Cancer

March 22, 2020

When checkpoint inhibitors were introduced, it had been more than 30 years since any new drugs had been approved for the treatment of urothelial cancer. Recently, 2 new non–checkpoint inhibitors, erdafitinib and enfortumab vedotin-ejfv, reached the market, and more may be available soon.

Patient-Centered Oncology: Working Together for Optimal Outcomes

December 07, 2019

As cancer therapies have evolved and individualized treatments have de-veloped over time, patient-centered care has become more prevalent, and oncology teams must consider it to maximize the chances of positive patient outcomes.